Tag: Drug Development

Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. It includes pre-clinical research on microorganisms and animals, filing for regulatory status for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug.

A Russian Vaccine Against Haemophilus Influenzae

This year, the Ministry of Health of the Russian Federation may increase the list of risk groups for mandatory vaccination against infections caused by Haemophilus influenzae. There is no local drug o...

A Russian Drug Gets Alzheimer’s Patients to Recover the Memory

Scientists of the Competence Center of National Technological Initiative (NTI according to Russian abbreviation) are developing a drug based on a fragment of the human protein Lynx1, which recovers th...

HHS, ASPR, BARDA Award Paratek 5-Year Contract for NUZYRA®

drug-development
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced that the Department of Health and Hum...

3P Biopharmaceuticals, In3Bio to Collaborate in Novel Anti-Tumor Treatment Development

3P Biopharmaceuticals, a contract development and manufacturing organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, a UK based bi...

ViiV Healthcare, Pfizer and Shionogi Announced Development of Investigational Antibody N6LS

viiv healthcare
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced that the company will be developing the investigation...

FDA Policies on Drug Development Analyzed by Experts

drug-development
The US Food and Drug Administration (FDA) heard from more than two dozen stakeholders on opportunities for the agency to promote more effective drug development programs at a public workshop at its he...

Regeneron Pharmaceuticals Updated on Phase III Development Program of Libtayo®

regeneron
Regeneron Pharmaceuticals, Inc. provided an update on the ongoing Phase 3 development program evaluating Libtayo® (cemiplimab), a PD-1 inhibitor, as monotherapy and combination therapy in first-line p...

The Russian Center for Precision Genome Editing Will Develop Drugs for Autoimmune Pathologies

The Russian Center for Precision Genome Editing and Genetic Technologies for Biomedicine, which has become one of the three centers for genomic research created within the framework of the national pr...

Avacta and ADC Therapeutics Join Forces to Develop Drug Conjugates

lab research
Pharma company Avacta Group PLC has signed a collaboration agreement with Swiss biotechnology firm ADC Therapeutics SA. Avacta’s lead candidate is Affimer, an alternative to antibodies, derived fro...

Innovent Biologics and Hutchison China MediTech Expand Global Collaboration Agreement

Innovent Biologics, Inc. and Hutchison China MediTech Limited announced the expansion of their global collaboration agreement to evaluate the safety and efficacy of Innovent’s Tyvyt® (sintilimab injec...

Numab and Eisai Agreed to Discover and Develop Multi-Specific Antibody Immunotherapies for Cancer

drug development
Numab Therapeutics AG announced the initiation of a partnership with Eisai, Co., Ltd (Eisai), under a research and option agreement, to discover and develop novel multi-specific antibody immunotherapi...

Chimerix Entered into Exclusive Global License Agreement with SymBio Pharmaceuticals

drug-development
Chimerix, a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and ...

BI and Inflammasome Entered into Co-Development and License Agreement

Boehringer Ingelheim and Inflammasome Therapeutics Inc. announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases. By ...

Astellas and iota Biosciences Announce Joint Research and Development Agreement

deal
Astellas Pharma Inc. and iota Biosciences, Inc. announced a joint research and development agreement to explore new biosensing and treatment measures using ultra-small implantable medical devices. Und...

Enable Injections Entered into Development Agreement with Genentech

Enable Injections has entered into a development agreement with Genentech. This partnership includes the potential for multiple molecule development programs including enFuse, under development by Ena...

Novo Holdings Invests over $10m in New Antibiotics’ Development

Small-molecule therapeutics company Curza received $5.25 million from the Novo Holdings REPAIR Impact Fund to help accelerate its lead programme focusing on a new class of antibiotics targeting drug-r...